HRTX, US4277461020

Heron Therapeutics stock heads toward November 9 results

Published on 10/30/2026 at 20:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Heron Therapeutics stock traded at 0.25 euros on Lang & Schwarz on Friday evening. The company will discuss third-quarter results on November 9.

November Results Set Investor Focus

  • Heron Therapeutics will report third-quarter results and discuss business highlights on November 9.
  • The company has scheduled the investor call and webcast for 8:30 a.m. Eastern Time.
HRTX, US4277461020, Illustration mit AI erstellt.

Heron Therapeutics announced on October 26 that it will report third-quarter 2026 results and discuss recent business highlights on Monday, November 9. The announcement was carried by Quiver Quantitative from a GlobeNewswire release.

November Results Set Investor Focus

The conference call and live webcast are scheduled for 8:30 a.m. Eastern Time. Heron said the event will cover the quarterly financial results and recent business developments, with an archived version available on the company's website for 60 days.

Heron describes itself as a commercial-stage biotechnology company focused on therapeutic innovations for acute-care and oncology patients. The upcoming report is the next scheduled company update for investors following the second quarter.

The real-time quote of Heron Therapeutics stock was 0.25 euros on Lang & Schwarz at 8:47 p.m. CET on Friday, October 30, 2026.

Heron Therapeutics at a glance

  • Company: Heron Therapeutics, Inc.
  • ISIN: US4277461020
  • Ticker: HRTX
  • Primary exchange: Nasdaq
  • Lang & Schwarz quote: 0.25 euros at 8:47 p.m. CET on October 30, 2026

Broader US equities are tracked through the S&P 500 market overview.

More updates are available in more news and analyses on Heron Therapeutics stock.

Disclaimer...
en | US4277461020 | HRTX | boerse | 70436657 |